Modality
siRNA
MOA
PD-L1i
Target
IL-13
Pathway
Complement
CFAS
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Feb 2029
Phase 1Current
NCT07008114
2,898 pts·CF
2017-06→2029-02·Not yet recruiting
2,898 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-202.9y awayPh2 Data· CF
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2029-02-20 · 2.9y away
CF
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07008114 | Phase 1/2 | CF | Not yet recr... | 2898 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |